ProShares比特以太等权重主动型ETF BETE 深 沪
交易中 06-29 10:31:21 美东时间
27.0008
0.000
0.00%
华盛通- 最 高0.00
- 今 开27.0008
- 成交量 144股
- 最 低 0.00
- 昨 收 27.0008
- 总市值 648.02万
- 52周最高 74.9685
- 市盈率 静 --
- 换手率 0.06%
- 52周最低 26.61
- 委 比 -14.29%
- 总股本 24.00万
- 历史最高 74.9685
- 量 比 1.08
- 振 幅 0.00%
- 历史最低 -6.3027
- 每 手 1
- 风险率 13.41%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BRIEF-EMA's CHMP Updates Mounjaro Product Information With Cardiovascular Data, No New Indication Granted
BRIEF-EMA's CHMP Updates Mounjaro Product Information With Cardiovascular Data, No New Indication Granted June 26 (Reuters) - EMA's CHMP: EMA'S CHMP -UPDATES MOUNJARO PRODUCT INFORMATION WITH CARDIOVASCULAR DATA, NO NEW INDICATION GRANTED EMA'S CHMP: ONSWIK RECEIVED A POSITIVE OPINION FROM THE CHMP
06-26 18:59
LIVE MARKETS-GLP-1 obesity, diabetes drug market to hit $150 billion in 2030, TD Cowen says
LIVE MARKETS-GLP-1 obesity, diabetes drug market to hit $150 billion in 2030, TD Cowen says U.S. indexes fall with Nasdaq leading losses, off ~1.7% Health, Staples lead S&P 500 sector gainers; Tech is weakest group Euro STOXX 600 index off ~0.04% Dollar rallies; US crude off >2%, gold down >2%; bitc
06-05 22:59
Medtronic Q4 revenue rises on growth in cardiovascular segment
Medtronic Q4 revenue rises on growth in cardiovascular segment Overview Healthcare technology firm's fiscal Q4 revenue rose 9.9% yr/yr to $9.81 bln Fiscal Q4 adjusted EPS was $1.55, GAAP EPS was $0.96 Company raised quarterly dividend Outlook Medtronic guides to FY27 organic revenue growth of 6.75%
06-03 18:57
BRIEF-Newcelx Submits Pre-IND Package To FDA For NCEL-101 For Treatment Of Type 1 Diabetes
BRIEF-Newcelx Submits Pre-IND Package To FDA For NCEL-101 For Treatment Of Type 1 Diabetes May 27 (Reuters) - NewcelX AG NCEL.O : SUBMITS PRE-IND PACKAGE TO THE FDA FOR NCEL-101 FOR THE TREATMENT OF TYPE 1 DIABETES PRE-IND MEETING WITH FDA SCHEDULED TO ADVANCE NCEL-101 TO FIRST-IN-HUMAN TRIAL TYPE B
05-27 20:00
NuWays raises Indus price target to EUR 37, keeps buy rating
NuWays raises Indus price target to EUR 37, keeps buy rating NuWays raised target price to EUR 37 from EUR 34.5, reiterated BUY, citing stronger-than-expected Q1 preliminary results driven by Material Solutions pricing. Q1 preliminary revenue rose 9.7% to EUR 442 million; adjusted EBITA nearly doubl
05-04 15:01
BRIEF-Sanofi's Tzield Approved In US To Delay Onset Of Stage 3 Type 1 Diabetes In Young Children
BRIEF-Sanofi's Tzield Approved In US To Delay Onset Of Stage 3 Type 1 Diabetes In Young Children April 22 (Reuters) - Sanofi SA SASY.PA : REG-PRESS RELEASE: SANOFI'S TZIELD APPROVED IN THE US TO DELAY THE ONSET OF STAGE 3 TYPE 1 DIABETES IN YOUNG CHILDREN FDA APPROVES TZIELD TO DELAY STAGE 3 TYPE 1
04-22 13:28
BRIEF-Eli Lilly To Sign $2 Bln Deal For AI Drug Development With Hong Kong Biotech Insilico Medicine - FT
BRIEF-Eli Lilly To Sign $2 Bln Deal For AI Drug Development With Hong Kong Biotech Insilico Medicine - FT March 29 (Reuters) - ELI LILLY TO SIGN $2BN DEAL FOR AI DRUG DEVELOPMENT WITH HONG KONG BIOTECH INSILICO MEDICINE - FT LILLY WILL ACQUIRE EXCLUSIVE RIGHTS TO SELL A GLP-1 DRUG FOR DIABETES FROM
03-29 19:06
BRIEF-Eledon Announces Updated Data From Investigator-Initiated Islet Transplant Trial Of Tegoprubart In Patients With Type 1 Diabetes At Uchicago Medicine
BRIEF-Eledon Announces Updated Data From Investigator-Initiated Islet Transplant Trial Of Tegoprubart In Patients With Type 1 Diabetes At Uchicago Medicine March 16 (Reuters) - Eledon Pharmaceuticals Inc ELDN.O : ELEDON ANNOUNCES UPDATED DATA FROM INVESTIGATOR-INITIATED ISLET TRANSPLANT TRIAL OF TEG
03-16 19:38
